LIM domain

:   Lin-l 1, Isl-1 and Mec-3 domain

bs

:   binding site

TMA

:   tissue micro-array

ChIP

:   chromatin immuno-precipitation

cBCC

:   cutaneous basal cell carcinoma

cSCC

:   cutaneous squamous cell carcinoma

cMM

:   cutaneous malignant melanoma

Introduction
============

To counteract DNA damage, specific mechanisms have been evolved, these are activated by specific signal transduction pathways, such as the phosphatidylinositol 3-kinase-like protein kinases (PIKKs) family, ATM, ATR and DNA-PK, and the members of the poly(ADP)ribose polymerase (PARP) family \[[@r1]--[@r7]\]. Among the effectors, a key role is played by the tumour suppressor protein p53 \[[@r8]--[@r15]\]. Indeed, DNA damage leads to p53 stabilisation by inhibition of interaction with its ubiquitin ligase, MDM2 \[[@r9]\], and as consequence, p53 transcriptionally induces cell cycle arrest, apoptosis or senescence. Among p53 targets in response to DNA damage, there are the CDK inhibitor p21, the pro-apoptotic proteins BAX and PUMA \[[@r16]\]. Moreover, p53 directly activates repair pathways such as nucleotide excision repair (NER) through regulation of the NER factors XPC and DDB2 and induces dNTP synthesis \[[@r17]\].

In addition to its roles in cell death, p53 has also been implicated in cytoskeleton assembly, cell motility and mechanosignaling, as negative regulator of cancer cell mobility, invasion and metastasis \[[@r18]--[@r20]\]. Integrin expression and signalling pathways, which play a key role in tumour cell invasion and metastasis, have been reported to be regulated indirectly by p53 \[[@r18]\]. For instance, Nutlin-3a, an MDM2 antagonist that acts as p53 activator, decreases the expression of integrin *alpha*5 in colorectal cancer and glioma cells \[[@r21],[@r22]\]; also the expression of integrin *beta*3 decreases upon DNA-damage in wild-type p53 expressing cells \[[@r23]\]. p53 also regulates focal adhesion and Rho signalling pathways by regulating Rho GTPase activity \[[@r24]\] and effector protein genes of RhoA/RhoC and Cdc42 pathways \[[@r25]--[@r28]\]. In addition, F-actin formation is negatively or positively regulated by p53 in response to DNA damage depending on the anti-tumour drug used and cell type. For instance, while doxorubicin increases the expression of RhoC and LIM kinase 2 in a p53-dependent manner promoting actin stress fibers formation \[[@r29]\], etoposide and camptothecin attenuate this process through p53-dependent expression of RhoE \[[@r30]\]. It has been also reported that upon etoposide-mediated DNA damage, p53 alters actin cytoskeleton by transcriptionally induction of the expression of the cytoskeleton adaptor protein ankyrin-1 \[[@r31]\]. The relevance of cytoskeleton remodelling and cell mobility in tumours is evidenced by the fact that mutant p53 promotes tumour cell invasion and results in loss of directionality during migration \[[@r32]\]. Cytoskeleton remodelling and cell migration in cancer is a complex process and is controlled by many proteins and pathways, the specific role of p53 in these mechanisms is not yet completely understood.

Here, we describe a novel p53 target gene, *ZNF185*, which codifies for a Zn-finger protein belonging to LIM-family, activated upon genotoxic stress caused by DNA-damaging drug etoposide. ZNF185 itself is not necessary for p53-dependent cell cycle arrest and apoptosis, yet its silencing affects actin cytoskeleton changes and cell polarity upon etoposide treatment. At mRNA and protein level, ZNF185 is strongly reduced in different types of epithelial tumours, including skin and head and neck squamous cell carcinomas, suggesting that depletion of ZNF185 in cancer cells facilitate cancer cell migration and spreading.

RESULTS
=======

ZNF185 is a p53 target gene
---------------------------

We have previously shown that the p53 family member p63, using a novel promoter region and a specific enhancer, directly regulated ZNF185 expression in keratinocytes \[[@r33]\]. To investigate whether also p53 could regulate ZNF185 expression and expand the p53 target genes involved in cytoskeleton regulation and cell polarity, we further analysed *ZNF185* promoter region using UCSC genome browser ([Fig 1A](#f1){ref-type="fig"}). We observed several regions showing high accessibility and conservation between the species, and an enrichment in different transcription factors (TF) binding. Analysis of the publicity available ChIP-seq data for p53 performed in MCF7 cells after p53 stabilization by nutlin (GSE86164 \[[@r34]\],), revealed a strong peak within *ZNF185* promoter only in nutlin-treated cells ([Fig 1B](#f1){ref-type="fig"}), suggesting p53 involvement in regulation of *ZNF185* transcription. Using previously described bioinformatic tool for p53 binding site (bs) prediction \[[@r35]\], we identified a putative binding site for p53 within the genomic region corresponding to the peak from the ChIP seq shown in [Fig 1B](#f1){ref-type="fig"} ([Fig 1C](#f1){ref-type="fig"}). Interestingly, this region is conserved only in primates and is absent in other species ([Fig 1C](#f1){ref-type="fig"}). To confirm physical binding of p53 on *ZNF185* promoter, we performed ChIP assay in p53 Tet-On inducible SaOs-2 cells previously generated in the laboratory \[[@r36]\]. As a positive control, we used the promoter of *CDKN1A*, the gene coding for p21 ([Fig 1D](#f1){ref-type="fig"}). To confirm if p53 could directly regulate *ZNF185* expression binding its promoter, we cloned the genomic locus harbouring p53 bs up-stream of the luciferase reporter gene. Luciferase activity assay showed a strong activation (120-fold, *P*\<0.01) upon p53 overexpression. Interestingly, the overexpression of the two different p53 mutants frequently found in human cancers (R175H and R273H) did not show any strong activation compared to the control ([Fig 1E](#f1){ref-type="fig"}), indicating that *ZNF185* is target of wild-type p53. Furthermore, the substitution of cytosines and guanines to adenines within *ZNF185* promoter sequence led to dramatic decrease of the luciferase activity (83% reduction, *P*\<0.01) upon p53 overexpression ([Fig 1F](#f1){ref-type="fig"}). To investigate if p53 is able to regulate *ZNF185* transcription, we induced p53 expression by doxycycline in SaOs-2 Tet-On cells and measured by RT-qPCR a significant increase of *ZNF185* mRNA after p53 induction paralleling *CDKN1A* increases (15-fold for *ZNF185* and 5-fold for *CDKN1A* at 24 h of induction, *P*\<0.05; [Fig 1G](#f1){ref-type="fig"}). We also confirmed this result changing cellular system. Indeed, overexpression of p53 in H1299 also led to a 20-fold increase of *ZNF185* mRNA, meanwhile the overexpression of two p53 mutants didn't show any significant modulation ([Fig 1H](#f1){ref-type="fig"}). Altogether, these data indicate *ZNF185* as a *bona fide* transcriptional target of wild-type p53.

![**ZNF185 is a transcription target of p53.** (**A**) UCSC genome browser analysis showing layered H3K4me3 mark in different cell lines, CpG islands, DNase clusters, conservation in vertebrates, and TF binding within *ZNF185* promoter. (**B**) Genomic locus of *ZNF185* showing the promoter region with H3K4me1 and p53 ChIP-seq signals after MCF7 treatment with either DMSO or nutlin. (**C**) Identified p53 binding site (p53 bs) within *ZNF185* promoter region and conservation analysis among primates. (**D**) Amplification of specific DNA fragments after ChIP performed in SaOs-2 Tet-On-p53-HA cells using HA antibody. (**E**) Luciferase activity assay in H1299 after transfection of pGL3-*ZNF185* promoter and either empty vector, p53 WT, p53-R175H, or p53-R273H expression vectors. \*\* *P*\<0.01, *n*=4. Western blot analysis of cell lysates confirms p53 overexpression. (**F**) Luciferase activity assay in H1299 after transfection of pGL3-*ZNF185* promoter with either WT of mutated p53 bs and either empty vector or p53 WT expression vectors. \*\* *P*\<0.01, *n*=3. Western blot analysis of cell lysates to confirm p53 overexpression. (**G**) RT-qPCR analysis of *ZNF185* and *CDKN1A* mRNA levels in SaOs-2 Tet-On-p53-HA after induction of p53 expression with 2 µg/mL doxycycline. \* *P*\<0.05, \*\* *P*\<0.01, *n*=3. Western blot shows p53 and p21 levels. (**H**) RT-qPCR analysis of *ZNF185* and *CDKN1A* mRNA levels in H1299 after transfection with empty vector, p53 WT, p53 R175H, or p53 R273H expression vectors. \*\* *P*\<0.01, *n*=3. Western blot shows p53 and p21 levels.](aging-10-101639-g001){#f1}

ZNF185 is up-regulated upon DNA damage
--------------------------------------

We investigated whether *ZNF185* is transcribed as consequence of p53 activation following DNA damage. Using two different carcinoma cell lines harbouring wild-type p53 (HCT116 and MCF7), we analysed ZNF185 expression after 0, 8, 16, and 24 hours of etoposide treatment. In both cases, we saw p53 stabilization as indicated by the western blots ([Fig 2 A-B](#f2){ref-type="fig"}) and, as a consequence of p53 activation, significant up-regulation of *ZNF185* mRNA (3-4-fold over control at 24 h of etoposide treatment, *P*\<0.05), and p21 as positive control, both at mRNA and protein levels ([Fig 2A-B](#f2){ref-type="fig"}). Interestingly, analysis of publicity available ChIP seq data (GSE56674 \[[@r37]\],) for p53 performed in keratinocytes showed that p53 binds to the locus within *ZNF185* promoter identified by us in this study. Moreover, this binding is observed only upon cisplatin or doxorubicin treatment ([Fig 2C](#f2){ref-type="fig"}). As a model of basal layer keratinocytes, we used the commercial cell line of immortalized keratinocytes, Ker-CT. We confirmed that also in Ker-CT cells etoposide treatment leads to p53 stabilization and ZNF185 up-regulation both at mRNA (3-fold, *P*\<0.01) and protein levels ([Fig 2D](#f2){ref-type="fig"}). To confirm that ZNF185 up-regulation is p53-dependent, we performed siRNA-mediated knock-down of p53 in Ker-CT cells. As expected, depletion of p53 abolished up-regulation of ZNF185 upon etoposide treatment ([Fig 2E](#f2){ref-type="fig"}). Since the major source of DNA damage in the human keratinocytes is UV irradiation, we irradiated Ker-CT cells and analysed ZNF185 level. Also in this case, we saw an up-regulation of ZNF185 at protein level. Altogether, these findings show that upon DNA damage we detected up-regulation of ZNF185 expression in p53-dependent manner both in tumour cell lines and in normal human keratinocytes.

![**ZNF185 is up-regulated upon DNA damage.** (**A**) qPCR analysis of *ZNF185* and *CDKN1A* mRNA levels in HCT116 after 25 µM etoposide treatment. \*\**P*\<0.01. Western blot shows ZNF185, p53, and p21 levels. (**B**) qPCR analysis of *ZNF185* and *CDKN1A* mRNA levels in MCF7 after 25 µM etoposide treatment. Western blot shows ZNF185, p53, and p21 levels. \**P*\<0.05 (**C**) Genomic locus of *ZNF185* showing the promoter region with H3K4me3 and p53 ChIP-seq signals after HEKn treatment with either DMSO, doxorubicin, or cisplatin. (**D**) qPCR analysis of *ZNF185* and *CDKN1A* mRNA levels in Ker-CT after 100 µM etoposide treatment. \*\**P* 0.05, *n*=3 (for *ZNF185*) and *n*=2 (for *CDKN1A*). Western blot shows ZNF185, p53, and p21 levels. (**E**) Western blot analysis of ZNF185, p53, and p21 levels after 100 µM etoposide treatment and p53 knock-down in Ker-CT cells. (**F**) Western blot analysis of ZNF185, p53, and p21 levels after 10 mJ^.^cm^-2^ UV-B treatment in Ker-CT cells for indicated times. Densitometry values of ZNF185 expression levels, normalized to GAPDH level, are shown.](aging-10-101639-g002){#f2}

ZNF185 is involved in the cytoskeleton remodelling upon DNA damage
------------------------------------------------------------------

Since the major functions of p53 activation upon DNA damage relate to the cell cycle arrest and apoptosis, we asked whether depletion of ZNF185 could alter cell cycle content under this specific stress condition. We performed siRNA mediated knock-down of ZNF185 in Ker-CT cells with two different siRNAs and treated the cells with etoposide. Cytofluorimetric analysis did not reveal any significant modulation in cell cycle distribution and apoptosis respect to the control ([Fig 3A](#f3){ref-type="fig"}). It was previously reported that ZNF185 regulates proliferation of prostate cancer cells \[[@r38]\], to further investigate this point we generated Ker-CT cell line, stably expressing shRNA against ZNF185 (shZNF185). We performed the EdU-incorporation assay to evaluate the number of cells in S-phase, but we did not observe any significant difference in cell proliferation respect to the control ([Fig 3B](#f3){ref-type="fig"}). Given that several LIM-domain Zn-fingers can migrate into the nucleus under stress conditions \[[@r39]\], we asked whether DNA damage can alter ZNF185 localisation. We found that ZNF185 localised in the cytoplasm and at the cell periphery ([Fig 3C](#f3){ref-type="fig"}) also after etoposide treatment. Due to the presence of the actin-interacting domain within ZNF185 protein, we hypothesised that ZNF185 could be involved in cytoskeleton remodelling upon DNA damage. To this aim, we performed immunofluorescence analysis using phalloidin as a marker of filamentous actin and vinculin as a marker of focal adhesion. Under normal conditions, most of the cells had migratory phenotype showing vinculin accumulation on the leading edge. After etoposide treatment, cells lost planar polarity as visualised by homogeneous vinculin distribution on the cell periphery (percentage of polarized cells from 100% to 35%). Surprisingly, this phenotype was abolished in the shZNF185 cells which retained planar polarization also upon etoposide treatment (percentage of polarized cells from 100% to 82%) ([Fig 3D](#f3){ref-type="fig"}). Altogether, these results suggest that ZNF185 is involved in the loss of the planar polarity of cells upon DNA damage.

![**ZNF185 is involved in the cytoskeleton remodelling upon DNA damage.** (**A**) FACS analysis of cell cycle content of the Ker-CT treated with either DMSO or 100 µM etoposide for 24 h after ZNF185 knock-down with two different siRNAs. Western blot confirms ZNF185 silencing. (**B**) EdU-incorporation assay by FACS showing % of EdU-positive Ker-CT shZNF185 cells. Western blot confirms the ZNF185 knock-down. (**C**) Immunofluorescence analysis of ZNF185 expression in Ker-CT treated with either DMSO or 100 µM etoposide for 16 h. Phalloidin was used for cytoskeleton staining. Scale bar: 50 µm. (**D**) Immunofluorescence analysis of vinculin distribution in Ker-CT treated with either DMSO or 100 µM etoposide and knocked-down for ZNF185. Phalloidin was used for cytoskeleton staining. Scale bar: 20 µm. In the right panel is shown the quantification of % of polarized cells in ten random fields. Western blot shows ZNF185, p53, and p21 levels.](aging-10-101639-g003){#f3}

ZNF185 is down-regulated in epithelial cancers
----------------------------------------------

p53 is frequently mutated in human cancers and we have shown that ZNF185 is positively regulated by wild-type p53, therefore we asked if ZNF185 level is decreased in epithelial cancers and particularly in the skin carcinomas. Firstly, we analysed *ZNF185* mRNA expression in different types of epithelial cancers from TCGA collection. Five cancer types - prostate adenocarcinoma (*PRAD*), chromophobe renal cell carcinoma (*KICH*), head and neck squamous cell carcinoma (*HNSC*), oesophageal carcinoma (*ESCA*), and adenoid cystic carcinoma (*ACC*) **--** showed a significant decrease in *ZNF185* mRNA level respect to the normal tissues from both TCGA and GTEx database ([Fig 4A](#f4){ref-type="fig"}). Furthermore, we analysed correlation between the expression of *ZNF185* and two distinct targets of p53 -- *PERP* and *CDKN1A*. Interestingly, a strong positive correlation was observed only in the cancers arising from squamous epithelia -- oesophageal and head and neck carcinomas ([Fig. 4B](#f4){ref-type="fig"}). Since there are only few datasets of skin cancer with a very low number of samples, we decided to analyse ZNF185 expression in skin cancer by immunohistochemistry using tissue microarray, containing 42 samples of the cutaneous squamous cell carcinoma (cSCC), 14 samples of the cutaneous basal cell carcinoma (cBCC), 12 samples of cutaneous malignant melanoma (cMM), and 10 samples of the normal skin. As a marker of proliferation, we used Ki67. Analysis of ZNF185 expression pattern at protein level in the normal skin confirmed previously published data from our laboratory \[[@r33]\], in which ZNF185 highest expression occurs in the differentiated spinous and granular layers ("SS/SG") of the epidermis with low expression in the proliferating basal layer ("SB"). Cornified layer ("SC") and dermis ("D") were found negative for ZNF185 ([Figure 5A](#f5){ref-type="fig"}). Analysis of skin cancer samples revealed that ZNF185 expression is dramatically down-regulated in the cutaneous squamous and basal cell carcinoma ("cSCC" and "cBCC") and malignant melanoma ("cMM") samples ([Figure 5B](#f5){ref-type="fig"}). Furthermore, ZNF185 was found only in well-differentiated subpopulations of squamous cell carcinoma ("WD" of cSCC) in contrast to poorly-differentiated basal-like subpopulations ("PD" of cSCC) ([Figure 5C](#f5){ref-type="fig"}). All the tumour samples showed a significant decrease (*P*\<1x10^-5^) of ZNF185 H-score respect to the differentiated layers of the normal epidermis ([Figure 5D](#f5){ref-type="fig"}). These findings reveal a dramatic down-regulation of ZNF185 at protein level in the skin cancer and suggest that ZNF185 could be a potential biomarker for epithelial cancer diagnosis and prognosis.

![**ZNF185 mRNA is down-regulated in epithelial cancer.** (**A**) Box-plot showing expression of ZNF185 mRNA in different types of cancer from the GTEx/TCGA datasets for normal samples (N) and TCGA datasets for tumour samples (T). \* *P*\<0.05. (**B**) Correlation analysis between the expression of *ZNF185* and either *PERP* or *CDKN1A* in ESCA and HNSC tumour samples from TCGA.](aging-10-101639-g004){#f4}

![**ZNF185 is down-regulated in skin cancer.** (**A**) Immunohistochemical analysis of ZNF185 expression in normal skin. Ki67 was used as a marker of proliferation. Scale bar: 100 µm. (**B**) Immunohistochemical analysis of ZNF185 expression in skin cancer: cutaneous basal cell (cBCC), squamous cell carcinoma (cSCC), and malignant melanoma (cMM). Ki67 was used as a marker of proliferation. Scale bar: 250 µm. (**C**) Immunohistochemical analysis of ZNF185 expression in cutaneous squamous cell carcinoma (well differentiated). Ki67 was used as a marker of proliferation. Scale bar: 50 µm. (**D**) Violin plot showing H-score of protein expression level of ZNF185 in the normal skin (D -- dermis, SB -- basal layer, SS/SG -- spinous and granular layers, SC -- cornified layer) and skin cancer (cSCC (cSCC subpopulations: PD -- poorly-differentiated cells, WD -- well-differentiated cells), cBCC, and cMM).](aging-10-101639-g005){#f5}

DISCUSSION
==========

Aging is complex set of genetic \[[@r40],[@r41]\], epigenetic \[[@r42]--[@r46]\], immunological \[[@r47]--[@r51]\], and metabolic \[[@r52]--[@r58]\] rearrangements, involving several cellular signalling pathways \[[@r59]--[@r63]\] able to regulate metabolism, ROS formation \[[@r64]--[@r71]\] and DNA Damage Response (DDR) \[[@r72]--[@r74]\] in all organs \[[@r75]--[@r77]\]. Therefore, the identification of novel pathways involving p53-mediated responses \[[@r78],[@r79]\] is of crucial interest. TP53 has been extensively studied in development and differentiation \[[@r14],[@r80]--[@r82]\] as well as in cancer progression \[[@r83],[@r84]\] and specifically in DDR \[[@r85]--[@r87]\]. The situation involves additional complexity if we consider that also the p53-related family members \[[@r88],[@r89]\], that is p63 \[[@r90]--[@r92]\] and p73 \[[@r93]\], may be involved in DDR. TP63 is a gene primarily related to skin development \[[@r94]\], metabolism \[[@r36],[@r95],[@r96]\] and epithelial homeostasis \[[@r97],[@r98]\] however, there is compelling evidence that it is also involved in cancer \[[@r27],[@r47],[@r99]--[@r103]\]. Similarly, TP73 is clearly involved in cancer \[[@r104]\], while the knockout studies \[[@r105],[@r106]\] indicate a clear involvement in metabolism \[[@r107]--[@r109]\], neuro-development \[[@r104],[@r110],[@r111]\] and cancer progression \[[@r112],[@r113]\]. Therefore, while the potential involvement of p73 with ZNF185 remains to be elucidated, the identification of a novel pathways of p53 regulating DDR via ZNF185 is of relevance.

Recently, the importance of actin-cytoskeleton remodelling and cell polarity during cancer cell spreading and metastasis has emerged \[[@r114]--[@r117]\], and p53 is in part involved in counteracting this specific aspect. Indeed, wild-type p53 can influence actin cytoskeleton dynamics controlling integrin and cadherin signalling and extracellular matrix degradation, suppressing EMT via different pathways \[[@r20],[@r23],[@r118]--[@r120]\]. Interestingly, also tumour microenvironment influences actin cytoskeleton \[[@r121],[@r122]\], in part repressing wild-type p53 functions \[[@r123]\]. In fact, when p53 is inactivated, cancer cells invasion increases \[[@r124]\]. Here, we demonstrated that p53 wild-type transcriptionally activates *ZNF185* in cells upon DNA damage, which could make part of p53 negative regulation of cancer cell mobility, invasion and metastasis. Interestingly, similarly to another p53 target gene Rap2B \[[@r125]\], down-regulation of ZNF185 does not affect cell cycle progression or cell death, but its silencing abolishes the actin cytoskeleton rearrangements and cell polarity changes upon etoposide treatment.

ZNF185 is an actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein \[[@r126]\]. The domain interacting with actin is located at the N-terminus, and it is necessary to mediate actin-cytoskeleton targeting of ZNF185, while the C-terminus LIM domain is dispensable for actin binding \[[@r38]\]. The LIM domain is a protein-protein interaction domain found in a wide range of proteins whose functions are related to the dynamics of the cytoskeleton \[[@r39],[@r127],[@r128]\]. In keratinocytes and epidermis ZNF185 has been described highly expressed in differentiating conditions, physically interacting with E-cadherin, a component of the adherens junctions, one of the critical cell-cell adhesive complexes crucial in the pluristratified epithelia \[[@r33]\]. ZNF185 involvement in pathologies, such as cancer \[[@r38]\], has not been completely investigated yet. Few studies reported ZNF185 as an unfavourable prognostic marker in ductal carcinoma of pancreas \[[@r129]\]. Its expression was found upregulated in colon cancer and likely correlated with liver metastasis \[[@r130]\]. On the other hand, other studies described epigenetic silencing of *ZNF185* associated with high grade and metastatic prostate tumours \[[@r131]\], lung tumours and head and neck squamous cell carcinomas \[[@r33],[@r132]--[@r134]\]. Recently, it was reported that ZNF185 expression is negatively correlated with lymph node metastasis of lung adenocarcinoma and its overexpression leads to down-regulation of p-AKT, p-GSK3β, VEGF and MMP-9 expression \[[@r135]\]. These studies suggest a possible tumour-specific contribution of ZNF185 expression in tumour formation.

We confirmed ZNF185 down-regulation in different epithelial tumours and, by analysing the expression of ZNF185 at protein level, we found a significant decrease of ZNF185 in all the tumour samples analysed. Moreover, we found ZNF185 positive signal only in well-differentiated subpopulations of squamous cell carcinoma in contrast to poorly-differentiated basal-like aggressive subpopulations, suggesting a tumour-suppressor role of ZNF185. The possible involvement of ZNF185 in cytoskeleton remodelling upon DNA damage suggests its role in the metastasis promotion which is in line with previous reports \[[@r135]\]. The identification of p53-ZNF185 axis could contribute to determine how p53 controls cell spreading by actin cytoskeletal remodelling, in which both the mechanical properties of the cytoskeleton of the cell as well as the microenvironment of the tumour cells seem to play an important role. Further investigation on the mechanisms by which p53 controls actin cytoskeleton reorganization and cell polarity, including the identification of novel target genes and pathways, would possibly be useful in developing new anti-cancer strategies and therapies.

MATERIALS AND METHODS
=====================

Cell culture, transfection, and treatments
------------------------------------------

Immortalized human epidermal keratinocytes Ker-CT (ATCC, Manassas, VA, USA) were cultured in EpiLife medium with addition of Human Keratinocyte Growth Supplements (HKGS, LifeTechnologies, Carlsbad, CA, USA). Human Non-Small-Cell Lung Carcinoma cells H1299 (ATCC), Human Osteosarcoma cells SaOs-2 inducible for p53 expression (SaOs-2 Tet-on p53), Human Colorectal Carcinoma cells HCT116 (ATCC), and mammary gland adenocarcinoma cells MCF7 (ATCC) were grown in DMEM medium with the addition of 10% FBS, 100 U penicillin, and 100 μg/mL streptomycin (Gibco, LifeTechnologies). For siRNA-mediated knock-down experiments, 2.5x10^5^ of cells were seeded on 60 mm culture dishes and the day after transfected with 80 pmol of specific siRNAs ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) by Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA). Cells were collected 48h posttransfection. For overexpression experiments, 1x10^6^ of cells were seeded in 100 mm culture dishes and the day after were transfected with 5 µg of plasmidic DNA using Lipofectamine 2000 transfection reagent (Invitrogen). Cells were collected 24 h later. For shRNA-mediated knock-down, 2.5x10^5^ of Ker-CT were infected at m.o.i. 10 with lentiviral particles carrying either scramble control shRNA (NC, Cat. No. VSC7078, Dharmacon, Lafayette, CO, USA) or specific shRNA for *ZNF185* (shZNF185, Cat. No. V3SVHSHC_5107270, Dharmacon). Transduced cells were selected by puromycin addiction to culture medium (1.5 µg/mL, Sigma, St. Louis, MO, USA). To induce DNA damage, cells were treated with either 25 µM or 100 µM etoposide (Sigma) or 0.02-0.40% DMSO (Sigma) for the indicated times or for 16 h if not otherwise indicated. Ker-CT cells were irradiated for indicated times with 10 mJ^.^cm^-2^ UV-B rays. p53 expression was induced in SaOs-2 Tet-On p53 cells by adding of 2 µg/mL doxycycline (Sigma) for the indicated times.

Western blotting
----------------

The cells were collected by trypsinization, washed in PBS and lysed in RIPA buffer (50 mM Tris-cl pH 7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM AEBSF, 1 mM DTT). 20-50 µg of total protein extracts were resolved in SDS polyacrylamide gel using the Mini-PROTEAN Tetra cell System (Bio-Rad, Hercules, CA, USA) and blotted onto a Hybond PVDF membrane (GE Healthcare, Chicago, IL, USA) using the Bio-Rad Mini Trans-Blot Cell system Bio-Rad). Membranes were blocked with 5% non-fat dry milk (Bio-Rad) in PBS/0.1% Tween-20 buffer, for 1 h at room temperature in agitation. Membranes were incubated with primary antibodies over night at +4 °C, washed and hybridized for 1 h at room temperature with the appropriate horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit and goat anti-mouse antibodies, Bio-Rad). Detection was performed with the ECL chemiluminescence kit (Perkin Elmer, Waltham, MA, USA). The following antibodies were used: anti-ZNF185 (1:300, Cat. No. HPA000400, Sigma), anti-GAPDH (1:15000, Cat. No. G8795, Sigma), anti-p53 (1:500, Cat. No. SC-126, Santa Cruz, Dallas, TX, USA), anti-p21 (1:300, Cat. No. SC-756, Santa Cruz), anti-HA (1:1000, Cat. No. 901502, BioLegend, San Diego, CA, USA).

RNA extraction and RT-qPCR analysis
-----------------------------------

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Total RNA (1 µg) was used for cDNA synthesis by GoScript Reverse Transcription System kit (Promega, Madison, WI, USA). RT-qPCRs were performed using the GoTaq Real-Time PCR System (Promega) in Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using appropriate qPCR primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). *TBP* was used as housekeeping gene for normalization. The expression of each gene was defined from the threshold cycle (C~t~), and relative expression levels were calculated using the 2^−ΔΔCt^ method. All reactions were run in triplicate.

Analysis of *ZNF185* genomic locus
----------------------------------

To analyse *ZNF185* genomic locus, different publicity accessible high-throughput sequencing data from ENCODE database (ChIP seq for H3K4me3 in different cell lines, CpG islands, DNase clusters, vertebrate conservation, TF binding) were visualised in the UCSC Genome Browser. Several ChIP-seq data from NCBI GEO database were analysed to assess p53 binding to the *ZNF185* promoter locus (GSE56674 (\[[@r37]\]) and GSE86164 (\[[@r34]\])). To identify putative p53 binding sites was used the "p53 scan" software \[[@r136]\]. The conservation analysis of *ZNF185* promoter locus was performed within UCSC genome browser.

Chromatin immunoprecipitation assay
-----------------------------------

1x10^6^ of SaOs Tet-On p53 cells, induced to overexpress p53 for 16 h, were used for ChIP assay. Cells were collected, fixed in 1% formaldehyde, and subjected to sonication for DNA shearing. The chromatin immunoprecipitation was performed with HA antibody (BioLegend) or unspecific immunoglobulin G (IgG, Invitrogen) using the MAGnify ChIP Kit (Invitrogen). Specific primers were used to amplify the putative p53 response element identified within *ZNF185* promoter region ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Luciferase activity assay
-------------------------

Promoter region of *ZNF185* containing the putative p53 binding site was amplified from human genomic DNA using specific primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). PCR products were digested by Kpn1/Nhe1 restriction enzymes (New England Biolabs, Ipswich, MA, USA) and subcloned into the pGL3-Promoter reporter vector (Promega). The constructs were completely sequenced. For luciferase activity assay, a total of 1.2x10^5^ H1299 cells were seeded in 12-well dishes 24 h before transfection. 100 ng of pGL3 reporter vector, 2 ng of pRL-CMV-Renilla luciferase vector (Promega) and 300 ng of either pcDNA-HA-p53, pcDNA-HA-p53-R175H, pcDNA-HA-p53-R273H, or empty pcDNA-HA vector (as a control) were cotransfected using Effectene transfection reagent according to the manufacturer's instructions (Qiagen). The luciferase activity was measured 24 h after transfection using a Dual Luciferase Reporter Assay System (Promega). The light emission was measured over 10 sec using a Lumat LB9507 luminometer (EG&GBerthold, Bad Wildbad, Germany). The transfection efficiency was normalized to Renilla luciferase activity. The overexpression of p53 was confirmed by western blotting.

Mutagenesis
-----------

For mutagenesis of p53 binding site was performed a PCR on 100 ng of pGL3 vector carrying p53 binding site using specific primers ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). PCR product was digested with DpnI restriction enzyme (New England Biolabs). The presence of mutated site was confirmed by sequencing.

Immunohistochemical staining and TMA
------------------------------------

The immunohistochemical staining of the skin cancer tissue microarray sections (US Biomax, Rockville, MD, USA) was performed using the BenchMark ULTRA slide staining system (Roche Diagnostics, Risch-Rotkreuz, Switzerland). The staining for Ki67 was performed using anti-Ki67 antibody (Cat. No. 790-4286, Ventana) following manufacturer's indications. For ZNF185 staining, samples were incubated at 95°C for 76 min in the Cell Conditioning solution CC1 (Roche) and stained with anti-ZNF185 antibody (1:100, Sigma) for 40 min. Sections were counterstained with Mayer's haematoxylin, dehydrated and mounted. Samples were scored using a semi-quantitative method. Cases were analysed for staining intensity, which was scored as 0 (not detected), 1+ (weak), 2+ (intermediate), and 3+ (strong). For each case, the histological "H-score" (0-300) was calculated by multiplying the percentage of positive cells (0%-100%) by the intensity (0-3).

Immunofluorescence
------------------

Ker-CT cells were seeded on 5 mm coverslips, fixed for 10 min in 10% formalin buffered solution, washed with PBS and permeabilized in 0.2% triton X-100 solution in PBS for 10 min. Sections were incubated for 1 h in 10% goat serum in PBS at room temperature and overnight at 4 ºC with primary antibodies. Following antibodies were used: anti-ZNF185 (1:50, Sigma) and anti-vinculin (1:300, BD Biosciences, Franklin Lakes, NJ, USA). Sections were incubated for 1 h at room temperature with secondary anti-mouse and anti-rabbit 488- or 568-AlexaFluor conjugated antibodies (Invitrogen, 1:1000) together with 1 μg/mL DAPI (Sigma) for nuclear DNA staining. For cytoskeleton staining, 488- or 568-AlexaFluor conjugated phalloidin was used (1:1000, Thermo Fisher Scientific, Waltham, MA, USA). Images were acquired by Nikon A1 confocal laser microscope using NIS elements software (Nikon, Tokyo, Japan).

Cell proliferation
------------------

The incorporation of EdU during DNA synthesis was evaluated using the Click-iT EdU flow cytometry assay kit according to the manufacturer\'s protocol (Thermo Fisher Scientific). The cell cycle was analysed using an Accuri C6 flow cytometer (BD Biosciences). Fifteen thousand events were evaluated using the Accuri C6 (BD Biosciences) software. For cell cycle analysis, cells were fixed in 50% methanol/acetone 4:1 mix for 30 min at +4 °C, then treated with 13 Kunitz U/mL RNase for 15 min and stained with 50 µg/mL of propidium iodide for 20 min. Twelve thousand events were acquired using FACScalibur (BD Biosciences). Cell cycle distribution was calculated using FloxJo software.

Bioinformatic analysis
----------------------

Analysis of ZNF185 expression in normal and tumour samples from TCGA/GTEx databases was performed using GEPIA \[[@r137]\]. *ZNF185*, *PERP*, and *CDKN1A* expression data in ESCA and HNSC samples from TCGA collection were obtained using R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl/>).

Statistical analysis
--------------------

The significance of differences between two experimental groups was calculated using unpaired, two-tailed Student's t-test. Values of *P* \< 0.05 were considered significant. For RT-qPCR and luciferase assay, values reported are the mean ± SD. For statistical analysis of TMA scoring was used Mann--Whitney U test. All statistical analyses were performed using GraphPad Prism 7.0 Software. Violin plots were generated in R using ggplot2 package.
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